Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: Can imaging results prior to interval debulking predict survival?

Journal of Gynecologic Oncology

Volumn 22, Issue 3, 2011, Pages 183-187

  Menczer, Joseph ^a   Usviatzov, Irena ^b   Ben Shem, Erez ^a   Golan, Abraham ^a   Levy, Tally ^a  

^a Gynecologic Oncology Unit   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Imaging results; Interval debulking; Neoadjuvant chemotherapy; Ovarian carcinoma; Survival prediction

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; IMAGING; KAPLAN MEIER METHOD; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; PERITONEUM CANCER; PREDICTION; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 80052971841     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2011.22.3.183     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
3. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55(3 Pt 2):S4-14.
4. Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 2000;19:11-9.
5. Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000;19:42-8.
6. Schwartz PE. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? Oncology (Williston Park) 2008;22:1118-25.
7. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2010;(10):CD006014.
8. Weinberg LE, Rodriguez G, Hurteau JA. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol 2010;101:334-43.
9. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
10. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166-72.
11. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532-40.
12. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004;101:346-52.
13. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-31.
14. Martinez-Said H, Rincon DG, Montes de Oca MM, Ruiz GC, Ponce JL, Lopez-Graniel CM. Predictive factors for irresectability in advanced ovarian cancer. Int J Gynecol Cancer 2004;14:423-30.
15. Le T, Faught W, Hopkins L, Fung-Kee-Fung M. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer. J Obstet Gynaecol Can 2008;30:665-70.
16. Le T, Hopkins L, Faught W, Fung-Kee-Fung M. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol 2007;105:712-5.
17. Tate S, Hirai Y, Takeshima N, Hasumi K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 2005;96:143-9.
18. Tiersten AD, Moon J, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, et al. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. Oncology 2009;77:395-9.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
20. Kang S, Kim TJ, Seo SS, Kim BG, Bae DS, Park SY. Role of extended chemotherapy in advanced ovarian cancer patients with high posttreatment serum CA-125 levels. Gynecol Obstet Invest 2011;72:50-4.
21. Brun JL, Rouzier R, Selle F, Houry S, Uzan S, Darai E. Neoadjuvant chemotherapy or primary surgery for stage III/ IV ovarian cancer: contribution of diagnostic laparoscopy. BMC Cancer 2009;9:171.